

Marc Vogel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3874165/publications.pdf>

Version: 2024-02-01

64
papers

1,150
citations

471371

17
h-index

434063

31
g-index

72
all docs

72
docs citations

72
times ranked

1674
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the “Bernese method”. Substance Abuse and Rehabilitation, 2016, Volume 7, 99-105.	1.6	146
2	Minimization of Childhood Maltreatment Is Common and Consequential: Results from a Large, Multinational Sample Using the Childhood Trauma Questionnaire. PLoS ONE, 2016, 11, e0146058.	1.1	129
3	Reduced volume of the nucleus accumbens in heroin addiction. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 637-645.	1.8	68
4	Treatment or “high” Benzodiazepine use in patients on injectable heroin or oral opioids. Addictive Behaviors, 2013, 38, 2477-2484.	1.7	65
5	Reduction of seclusion on a hospital-wide level: Successful implementation of a less restrictive policy. Journal of Psychiatric Research, 2014, 54, 94-99.	1.5	56
6	There is no age limit for methadone: a retrospective cohort study. Substance Abuse Treatment, Prevention, and Policy, 2011, 6, 9.	1.0	37
7	A randomized, controlled trial of combined cognitive-behavioral therapy plus prize-based contingency management for cocaine dependence. Drug and Alcohol Dependence, 2014, 145, 94-100.	1.6	34
8	Clinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence. Substance Abuse and Rehabilitation, 2015, 6, 61.	1.6	34
9	A pilot randomized trial of exercise as adjunct therapy in a heroin-assisted treatment setting. Journal of Substance Abuse Treatment, 2017, 76, 49-57.	1.5	34
10	One size does not fit all—evolution of opioid agonist treatments in a naturalistic setting over 23 years. Addiction, 2019, 114, 103-111.	1.7	29
11	Cost of attempted suicide: a retrospective study of extent and associated factors. Swiss Medical Weekly, 2012, 142, w13648.	0.8	29
12	Reduction in Cerebral Perfusion after Heroin Administration: A Resting State Arterial Spin Labeling Study. PLoS ONE, 2013, 8, e71461.	1.1	27
13	Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial. Addiction Science & Clinical Practice, 2021, 16, 11.	1.2	26
14	Prolonged use of benzodiazepines is associated with childhood trauma in opioid-maintained patients. Drug and Alcohol Dependence, 2011, 119, 93-98.	1.6	24
15	Effects of cortisol administration on craving in heroin addicts. Translational Psychiatry, 2015, 5, e610-e610.	2.4	24
16	Abnormal functional integration of thalamic low frequency oscillation in the BOLD signal after acute heroin treatment. Human Brain Mapping, 2015, 36, 5287-5300.	1.9	22
17	Association between methadone dose and concomitant cocaine use in methadone maintenance treatment: a register-based study. Substance Abuse Treatment, Prevention, and Policy, 2014, 9, 46.	1.0	19
18	Experiences with take-home dosing in heroin-assisted treatment in Switzerland during the COVID-19 pandemic—Is an update of legal restrictions warranted?. International Journal of Drug Policy, 2022, 101, 103548.	1.6	19

#	ARTICLE	IF	CITATIONS
19	Tincture of opium for treating opioid dependence: a systematic review of safety and efficacy. <i>Addiction</i> , 2017, 112, 415-429.	1.7	17
20	Rethinking retention in treatment of opioid dependenceâ€”The eye of the beholder. <i>International Journal of Drug Policy</i> , 2017, 39, 109-113.	1.6	16
21	Effect of Door-Locking Policy on Inpatient Treatment of Substance Use and Dual Disorders. <i>European Addiction Research</i> , 2017, 23, 87-96.	1.3	15
22	Chronic Pain Among Homeless Persons with Mental Illness. <i>Pain Medicine</i> , 2017, 18, 2280-2288.	0.9	15
23	Shifting North American drug markets and challenges for the system of care. <i>International Journal of Mental Health Systems</i> , 2021, 15, 86.	1.1	15
24	A comprehensive model of treatment participation in chronic disease allowed prediction of opioid substitution treatment participation in Zurich, 1992â€”2012. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 1346-1354.	2.4	14
25	Comparing opium tincture and methadone for medicationâ€”assisted treatment of patients with opioid use disorder: Protocol for a multicenter parallel group noninferiority doubleâ€”blind randomized controlled trial. <i>International Journal of Methods in Psychiatric Research</i> , 2019, 28, e1768.	1.1	14
26	Hepatitis C prevalence and associated risk factors among individuals who are homeless and diagnosed with mental illness: At Home/Chez Soi Study, Vancouver, BC. <i>European Journal of Public Health</i> , 2019, 29, 242-247.	0.1	13
27	Patients with nonâ€”substanceâ€”related disorders report a similar profile of childhood trauma experiences compared to heroinâ€”dependent patients. <i>American Journal on Addictions</i> , 2017, 26, 215-220.	1.3	12
28	Effects of Psychoactive Substances in Schizophrenia â€” Findings of Structural and Functional Neuroimaging. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 2426-2433.	1.0	11
29	Methylphenidate for Attention-Deficit and Hyperactivity Disorder in Adult Patients With Substance Use Disorders: Good Clinical Practice. <i>Frontiers in Psychiatry</i> , 2020, 11, 540837.	1.3	11
30	Similar and Different? Subjective Effects of Methylphenidate and Cocaine in Opioid-Maintained Patients. <i>Journal of Psychoactive Drugs</i> , 2016, 48, 93-100.	1.0	10
31	Cannabis use in Switzerland 2015â€”2045: A population survey based model. <i>International Journal of Drug Policy</i> , 2019, 69, 55-59.	1.6	10
32	New Approaches in Drug Dependence: Opioids. <i>Current Addiction Reports</i> , 2021, 8, 298-305.	1.6	10
33	Can routine data from prisonersâ€™ files be used to estimate prevalence rates of illicit drug use among prisoners?. <i>International Journal of Public Health</i> , 2018, 63, 33-40.	1.0	9
34	Addressing fentanyl use disorder with fentanyl-assisted treatment. <i>Lancet Psychiatry</i> , 2022, 9, 103-105.	3.7	9
35	â€œOne prick and then itâ€™s doneâ€: a mixed-methods exploratory study on intramuscular injection in heroin-assisted treatment. <i>Harm Reduction Journal</i> , 2021, 18, 134.	1.3	9
36	Brain volume changes after longâ€”term injectable opioid treatment: A longitudinal voxelâ€”based morphometry study. <i>Addiction Biology</i> , 2021, 26, e12970.	1.4	8

#	ARTICLE	IF	CITATIONS
37	Coercion in substance use disorders: clinical course of compulsory admissions in a Swiss psychiatric hospital. <i>Swiss Medical Weekly</i> , 2018, 148, w14644.	0.8	8
38	Chronic High-Dose Buprenorphine Does Not Block Subjective High from Diacetylmorphine in a Patient in Heroin-Assisted Treatment. <i>Journal of Psychoactive Drugs</i> , 2019, 51, 377-382.	1.0	7
39	Co-occurring Mental Disorders in Transitional Aged Youth With Substance Use Disorders – A Narrative Review. <i>Frontiers in Psychiatry</i> , 2022, 13, 827658.	1.3	7
40	Chronic Pain among Individuals Experiencing Homelessness and Its Interdependence with Opioid and Other Substance Use and Mental Illness. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5.	1.2	7
41	Early Screening for Posttraumatic Stress Disorder in Inpatient Detoxification and Motivation Treatment: Results and Consequences. <i>European Addiction Research</i> , 2018, 24, 128-136.	1.3	6
42	Nasal Opioid Agonist Treatment in Patients with Severe Opioid Dependence: A Case Series. <i>European Addiction Research</i> , 2022, 28, 80-86.	1.3	6
43	Psychosis After Switch in Opioid Maintenance Agonist and Risperidone-Induced Pisa Syndrome: Two Critical Incidents in Dual Diagnosis Treatment. <i>Journal of Dual Diagnosis</i> , 2017, 13, 157-165.	0.7	5
44	Retention in the Austrian opioid agonist treatment system: a national prospective cohort study. <i>Harm Reduction Journal</i> , 2021, 18, 25.	1.3	5
45	Towards an International Consensus on the Prevention, Treatment, and Management of High-Risk Substance Use and Overdose among Youth. <i>Medicina (Lithuania)</i> , 2022, 58, 539.	0.8	5
46	Nasal administration of diacetylmorphine improved the adherence in a patient receiving heroin-assisted treatment. <i>Harm Reduction Journal</i> , 2022, 19, .	1.3	5
47	Stability of trauma-related symptoms during acute substance use treatment. <i>Journal of Addictive Diseases</i> , 2016, 35, 161-168.	0.8	4
48	Treatment approaches and outcome trajectories for youth with high-risk opioid use: A narrative review. <i>Microbial Biotechnology</i> , 2021, , .	0.9	4
49	Evaluation of medication-assisted treatment of opioid dependence – The physicians' perspective. <i>Drug and Alcohol Dependence</i> , 2016, 164, 106-112.	1.6	3
50	Agomelatine and Transient Elevation of Creatine Phosphokinase. <i>Drug Research</i> , 2016, 66, 614-616.	0.7	3
51	Association of Substance Use Patterns with Psychiatric Disorders in Homeless Persons with Psychiatric Disorders in Vancouver. <i>International Journal of Mental Health and Addiction</i> , 2019, 17, 1200-1213.	4.4	3
52	Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice – Identifying Group Differences and Predictors. <i>Frontiers in Psychiatry</i> , 2022, 13, 846834.	1.3	3
53	Mental health among opiate users in Kabul. <i>Intervention</i> , 2012, 10, 146-155.	0.2	2
54	Are Substance Use and Mental Illness Associated to an Earlier Onset of Homelessness?. <i>Mental Health in Family Medicine</i> , 2016, 12, .	0.2	2

#	ARTICLE	IF	CITATIONS
55	Effectiveness of Prenatal Screening for Substance Use: Critical Consciousness, A Promising Curriculum for Compassionate Screening. <i>Mental Health in Family Medicine</i> , 2017, 13, .	0.2	2
56	Novel remote electronic medication supply model for opioid-dependent outpatients with polypharmacyâ€”first long-term case study. <i>Harm Reduction Journal</i> , 2017, 14, 56.	1.3	1
57	Employment and paid work among participants in a randomized controlled trial comparing diacetylmorphine and hydromorphone. <i>International Journal of Drug Policy</i> , 2018, 57, 18-24.	1.6	1
58	Impact of an infection control service in a university psychiatric hospital: significantly lowering healthcare-associated infections during 18 years of surveillance. <i>Journal of Hospital Infection</i> , 2020, 106, 343-347.	1.4	1
59	Novel Medication Supply Model Guarantees Adequate Management and High Adherence to Polypharmacy in Older Opioid Users â€” Preliminary Results with Outpatients. <i>Journal of Aging Science</i> , 2017, 05, .	0.5	1
60	Offene TÃ¼ren in der Akutbehandlung von AbhÃ¤ngigkeitserkrankungen. <i>Swiss Archives of Neurology, Psychiatry and Psychotherapy</i> , 0, , .	0.4	1
61	Opening the Doors of a Substance Use Disorder Wardâ€”Benefits and Challenges From a Consumer Perspective. <i>Frontiers in Psychiatry</i> , 2020, 11, 580885.	1.3	1
62	Effective drug therapy for cocaine dependence: a milestone. <i>Lancet, The</i> , 2016, 387, 2171-2173.	6.3	0
63	Psychotherapieforschung bei Suchterkrankungen. , 2019, , 67-79.		0
64	Sedativa und Hypnotika. , 2019, , 259-278.		0